Lyell Immunopharma (LYEL) AI Stock Analysis

• Market Cap: $708.06M
• Dividend Yield: N/A
• Average Volume (3M): 28.02K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.63
• Revenue Growth: -34.92%
• EPS Growth: -43.26%
• Country: US
• Employees: 300
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -2.13
• Shares Outstanding: 21,243,954
• 10 Day Avg. Volume: 32,893
• 30 Day Avg. Volume: 28,022
• PEG Ratio: -0.01
• Price to Book (P/B): 0.44
• Price to Sales (P/S): 2743.40
• P/FCF Ratio: -1.03
• Enterprise Value/Market Cap: 0.04
• Enterprise Value/Revenue: 734.67
• Enterprise Value/Gross Profit: 734.67
• Enterprise Value/Ebitda: -0.16
• 1Y Price Target: $20.00
• Price Target Upside: -20.79% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: $30.00 ▲(18.81% Upside)

Lyell Immunopharma's overall stock score is primarily influenced by its challenging financial performance and valuation, which are offset by strong technical momentum and positive corporate developments. The financial instability and negative profitability weigh heavily on the score, but recent strategic moves and promising clinical data provide a positive outlook.

Positive Factors

Clinical Trial Success

High response rates in clinical trials suggest strong efficacy of Lyell's CAR T-cell therapies, enhancing its competitive position in oncology.

Pipeline Expansion

The acquisition of LYL273 strengthens Lyell's pipeline, potentially transforming treatment options for colorectal cancer and expanding market opportunities.

Strategic Partnerships

Partnerships and licensing agreements bolster Lyell's R&D capabilities and market reach, supporting long-term growth and innovation in cell therapies.

Negative Factors

Revenue Decline

Significant revenue decline indicates challenges in monetizing products, affecting financial sustainability and ability to fund future R&D.

Profitability Challenges

Severe profitability issues highlight operational inefficiencies and cost management challenges, potentially hindering long-term financial health.

Cash Flow Struggles

Ongoing cash flow challenges limit Lyell's ability to invest in growth opportunities and maintain operational stability, impacting future prospects.

Lyell Immunopharma Business Overview & Revenue Model

Company Description

Lyell Immunopharma (LYEL) is a biotechnology company focused on developing innovative cell therapies to treat cancer, particularly solid tumors. The company operates within the biopharmaceutical sector and utilizes its proprietary technology platform to engineer T cells for enhanced anti-tumor activity. Lyell's core products include a pipeline of cell therapy candidates aimed at improving the efficacy and safety of cancer treatments, leveraging advancements in immunotherapy.

How the Company Makes Money

Lyell Immunopharma generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which may include upfront payments, milestone payments tied to clinical progress, and royalties on product sales. The company may also receive funding through government grants or research contracts aimed at advancing its therapeutic candidates. Additionally, if Lyell's therapies receive regulatory approval and reach the market, the company could generate significant revenue from the sale of its cell therapies, contributing to its overall financial performance.

Lyell Immunopharma Financial Statement Overview

Summary

Lyell Immunopharma is facing significant financial challenges, particularly in terms of profitability and cash flow generation. The income statement reveals a substantial decline in revenue and high operational losses. The balance sheet shows some stability with low leverage, but negative profitability and cash flow trends pose substantial risks to financial health.

Income Statement

Lyell Immunopharma's income statement reveals significant challenges. The company has experienced a substantial decline in revenue over the TTM period, with a negative revenue growth rate of -31.67%. Profitability metrics are concerning, with a net profit margin of -5523.28% and negative EBIT and EBITDA margins, indicating high operational losses relative to revenue. These figures highlight the company's struggle to achieve profitability and manage costs effectively.

Balance Sheet

The balance sheet shows a moderate level of financial stability. The debt-to-equity ratio is relatively low at 0.16, suggesting manageable leverage. However, the return on equity is negative at -85.58%, reflecting significant losses relative to shareholder equity. The equity ratio is not explicitly calculated, but the company's equity position appears stable compared to its total assets.

Cash Flow

Cash flow analysis indicates ongoing cash flow challenges. The operating cash flow to net income ratio is negative, and the free cash flow growth rate is slightly negative at -3.76%. The free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is marginally covering net losses. Overall, the company faces difficulties in generating positive cash flow from operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	41.00K	61.00K	130.00K	84.68M	10.65M	7.76M
Gross Profit	41.00K	61.00K	130.00K	84.68M	10.65M	7.76M
EBITDA	-190.41M	-200.64M	-226.76M	-169.04M	-201.15M	-215.43M
Net Income	-325.66M	-342.99M	-234.63M	-183.12M	-250.22M	-204.47M
Balance Sheet
Total Assets	407.96M	490.86M	750.03M	937.56M	1.13B	908.28M
Cash, Cash Equivalents and Short-Term Investments	319.62M	370.53M	546.22M	640.15M	614.79M	612.62M
Total Debt	44.28M	58.97M	63.17M	67.70M	67.82M	54.57M
Total Liabilities	78.84M	108.03M	95.08M	104.31M	197.62M	189.84M
Stockholders Equity	329.12M	382.82M	654.95M	833.25M	929.79M	718.44M
Cash Flow
Free Cash Flow	-165.53M	-162.86M	-166.38M	-193.83M	-191.75M	-212.35M
Operating Cash Flow	-165.01M	-162.39M	-163.69M	-169.56M	-126.25M	-160.87M
Investing Cash Flow	138.97M	122.42M	184.05M	-11.54M	-121.57M	-273.52M
Financing Cash Flow	50.62M	1.33M	1.74M	10.63M	401.24M	476.79M

Lyell Immunopharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 25.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LYEL, the sentiment is Positive. The current price of 25.25 is below the 20-day moving average (MA) of 27.42, above the 50-day MA of 21.26, and above the 200-day MA of 13.40, indicating a bullish trend. The MACD of 3.82 indicates Negative momentum. The RSI at 73.41 is Negative, neither overbought nor oversold. The STOCH value of 72.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LYEL.

Lyell Immunopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LYEL	60 Neutral	$708.06M	-1.45	-75.75%	―	-34.92%	-43.26%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EDIT	49 Neutral	$228.43M	-0.98	-211.37%	―	-24.90%	7.19%
IMAB	45 Neutral	―	―	―	―	-100.00%	72.45%
MREO	43 Neutral	$318.19M	-7.59	-69.98%	―	―	―
REPL	42 Neutral	$775.02M	-2.74	-96.24%	―	―	-15.77%
RCKT	40 Underperform	$349.56M	-1.44	-74.88%	―	―	18.39%

Lyell Immunopharma Corporate Events

Lyell Immunopharma Presents Promising CAR T-Cell Data

On December 7, 2025, Lyell Immunopharma presented promising data at the American Society of Hematology Annual Meeting from its clinical trial of ronde-cel, a CAR T-cell product for treating relapsed or refractory large B-cell lymphoma. The trial showed high response rates and manageable safety profiles, with 93% overall response in third-line patients and 83% in second-line patients, indicating potential advancements in treatment options for heavily pre-treated patients.

Lyell Immunopharma Modernizes Bylaws for Shareholder Engagement

On December 3, 2025, Lyell Immunopharma‘s Board of Directors amended the company’s bylaws to modernize stockholder proposal procedures and disclosure requirements. These changes aim to streamline processes, clarify voting standards, and ensure compliance with Delaware General Corporation Law, potentially impacting shareholder engagement and corporate governance.

Lyell Immunopharma Secures Global Rights for LYL273

On November 6, 2025, Lyell Immunopharma entered into an Exclusive License Agreement with Innovative Cellular Therapeutics Holdings Limited, granting Lyell global rights to develop and commercialize LYL273, a CAR T-cell product for metastatic colorectal cancer, excluding certain Asian territories. The agreement includes significant financial commitments and potential milestone payments. The acquisition of LYL273, which has shown promising results in early clinical trials, is expected to enhance Lyell’s solid tumor pipeline and potentially transform the treatment landscape for colorectal cancer. The transaction is anticipated to have a modest impact on Lyell’s 2025 operating expenses, with the company’s cash reserves projected to support operations into 2027.

Lyell Immunopharma Appoints New Financial Leadership Team

On October 31, 2025, Lyell Immunopharma announced key leadership changes, appointing Lynn Seely, M.D. as interim principal financial officer and Veronica Sanchez Bulis as principal accounting officer. These appointments are part of the company’s strategic efforts to strengthen its financial leadership and ensure robust financial operations, potentially impacting its market positioning and stakeholder confidence.

Lyell Immunopharma CFO Resignation Announced

On September 15, 2025, Charles Newton announced his resignation as Chief Financial Officer of Lyell Immunopharma, effective October 31, 2025. The company will search for a replacement and has entered a consulting agreement with Newton to provide services until April 30, 2026.